| Literature DB >> 34467638 |
Katrin Peckert-Maier1, Alfrun Schönberg2, Andreas B Wild1, Dmytro Royzman1, Gabriele Braun2, Lena Stich1, Karina Hadrian2, Philipp Tripal3, Claus Cursiefen2, Alexander Steinkasserer1, Elisabeth Zinser1, Felix Bock2.
Abstract
Immune responses reflect a complex interplay of cellular and extracellular components which define the microenvironment of a tissue. Therefore, factors that locally influence the microenvironment and re-establish tolerance might be beneficial to mitigate immune-mediated reactions, including the rejection of a transplant. In this study, we demonstrate that pre-incubation of donor tissue with the immune modulator soluble CD83 (sCD83) significantly improves graft survival using a high-risk corneal transplantation model. The induction of tolerogenic mechanisms in graft recipients was achieved by a significant upregulation of Tgfb, Foxp3, Il27, and Il10 in the transplant and an increase of regulatory dendritic cells (DCs), macrophages (Mφ), and T cells (Tregs) in eye-draining lymph nodes. The presence of sCD83 during in vitro DC and Mφ generation directed these cells toward a tolerogenic phenotype leading to reduced proliferation-stimulating activity in MLRs. Mechanistically, sCD83 induced a tolerogenic Mφ and DC phenotype, which favors Treg induction and significantly increased transplant survival after adoptive cell transfer. Conclusively, pre-incubation of corneal grafts with sCD83 significantly prolongs graft survival by modulating recipient Mφ and DCs toward tolerance and thereby establishing a tolerogenic microenvironment. This functional strategy of donor graft pre-treatment paves the way for new therapeutic options in the field of transplantation.Entities:
Keywords: basic (laboratory) research/science; corneal transplantation/ophthalmology; dendritic cell; immunosuppression/immune modulation; macrophage/monocyte biology: differentiation/maturation; soluble CD83; tolerance
Mesh:
Year: 2021 PMID: 34467638 DOI: 10.1111/ajt.16824
Source DB: PubMed Journal: Am J Transplant ISSN: 1600-6135 Impact factor: 8.086